Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation
Primary Purpose
End Stage Renal Disease, Acute Renal Failure, Hemodialysis Catheter Infection
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Sodium Bicarbonate Catheter Lock Solution
Normal Saline Catheter Lock Solution
Sponsored by
About this trial
This is an interventional prevention trial for End Stage Renal Disease focused on measuring Central Venous Catheters, End Stage Renal Disease, Hemodialysis, Catheter-related infection, Catheter loss due to clot formation, Acute Renal Failure
Eligibility Criteria
Inclusion Criteria:
- Patients presenting over the age of 18 requiring hemodialysis via CVCs were eligible.
Exclusion Criteria:
- Having a poor venous system with inadequate blood flow for appropriate HD.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Normal Saline Catheter Lock Solution Group
Sodium Bicarbonate Catheter Lock Solution
Arm Description
Patients receiving normal saline catheter locking solution
Patients receiving sodium bicarbonate catheter locking solution
Outcomes
Primary Outcome Measures
Lumen Clot Formation
Catheter Loss Due to Lumen Clot Formation
Catheter Related Infection
Catheter Loss Due to Catheter Related Infection
Malfunction
Catheter Loss Due to Malfunction
Overall Cause
Catheter Loss Due to All Causes
Secondary Outcome Measures
Death
Number of deaths reported during the study period
Arrhythmia
Incidence of significant arrhythmia during dialysis requiring urgent intervention
Hemodynamic Instability
Incidence of extreme hypotension or hypertension requiring urgent intervention
Full Information
NCT ID
NCT03627884
First Posted
July 12, 2018
Last Updated
August 8, 2018
Sponsor
Coney Island Hospital, Brooklyn, NY
1. Study Identification
Unique Protocol Identification Number
NCT03627884
Brief Title
Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation
Official Title
Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation
Study Type
Interventional
2. Study Status
Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
October 1, 2016 (Actual)
Primary Completion Date
March 30, 2018 (Actual)
Study Completion Date
March 30, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Coney Island Hospital, Brooklyn, NY
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Prospective, randomized, comparative clinical and open-label trial comparing sodium bicarbonate catheter lock solution (SBCLS) to normal saline catheter lock solution (NSCLS) use in HD patients with central venous catheters (CVC).
Detailed Description
A randomized, comparative clinical, open-label trial at Coney Island Hospital, in Brooklyn, NY. The study period was between October 1, 2016 and March 30, 2018, a total of 546 days. All patients provided written informed consent before enrollment. The trial protocol was approved by Maimonides Medical Center Investigational Review Board: Study #2015-06-25-CIH. Patients presenting over the age of 18 requiring hemodialysis via CVCs were eligible. One patient was excluded due to having a poor venous system with inadequate blood flow for appropriate HD. No other patient was excluded from the study.
A total of 451 patients undergoing HD with CVCs were included in the study. Patients had tunneled internal jugular vein (IJV) catheters, non-tunneled IJV catheters, and non-tunneled femoral vein catheters. All patients were randomly assigned based on simple sequential order into one of two groups: NSCLS (n = 226) and SBCLS (n = 225). NSCLS patients were assigned between October 1, 2016 and June 30, 2017. SBCLS patients were assigned between July 1 2017 and March 30, 2018. Recruitment ended based on the similar number of enrolled participants between groups. A primary or co-investigator enrolled the participant into the trial and assigned the participant to the intervention at the time of presentation. Both groups received heparin-free HD treatment. Before each HD treatment, catheters and connections were inspected for leaks, evidence of damage, exit-site infection and tunnel infection. Intraluminal SBCLS or NSCLS lock solution was removed before connecting the HD catheter to a dialysis machine prior to any treatment.
During each treatment, patients were monitored for complications and standard care was provided to every patient. After each treatment, blood was rinsed from dialysis lines with NS solution back to the patient. Upon the conclusion of treatment, all catheters were flushed and locked with 10 mL of NSCLS or SBCLS, respective of their groups. Approximately 2 mL of the injected solution remained locked within the catheter. Catheter exit site dressing changes occurred after each HD treatment.
For patients that had clotted catheters, thrombolytic therapy was not instituted. Risk assessment performed by our hospital's risk management department determined that the net risk of thrombolytic use in their opinion was greater than the risk of catheter replacement by our qualified operators.
CVCs used in the study varied according to the patient's needs and consisted of Mahurkar non-tunneled catheters and Palindrome tunneled catheters. All CVCs were inserted by an expert operator under strict aseptic protocol. Catheter care was performed by trained dialysis staff according to our hospital's Administrative Policy and Procedure Manual. At the end of dialysis, all catheters were flushed and locked with one of two solutions. SBCLS contained 7.5% or 8.4% SB at a pH of 7.0-8.5, and was used to lock SBCLS-group catheters. NSCLS contained 0.9% sodium chloride at a pH 4.5-7.0, and was used to lock NSCLS-group patient catheters. Both are sterile non-pyrogenic solutions.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
End Stage Renal Disease, Acute Renal Failure, Hemodialysis Catheter Infection, Hemodialysis Complication, Hemodialysis Access Failure, Hemodialysis Catheter-Associated Bacteremia
Keywords
Central Venous Catheters, End Stage Renal Disease, Hemodialysis, Catheter-related infection, Catheter loss due to clot formation, Acute Renal Failure
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
451 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Normal Saline Catheter Lock Solution Group
Arm Type
Active Comparator
Arm Description
Patients receiving normal saline catheter locking solution
Arm Title
Sodium Bicarbonate Catheter Lock Solution
Arm Type
Active Comparator
Arm Description
Patients receiving sodium bicarbonate catheter locking solution
Intervention Type
Drug
Intervention Name(s)
Sodium Bicarbonate Catheter Lock Solution
Intervention Description
Using Sodium Bicarbonate Catheter Lock Solution
Intervention Type
Drug
Intervention Name(s)
Normal Saline Catheter Lock Solution
Intervention Description
Using Sodium Bicarbonate Catheter Lock Solution
Primary Outcome Measure Information:
Title
Lumen Clot Formation
Description
Catheter Loss Due to Lumen Clot Formation
Time Frame
Approximately 18 months
Title
Catheter Related Infection
Description
Catheter Loss Due to Catheter Related Infection
Time Frame
Approximately 18 months
Title
Malfunction
Description
Catheter Loss Due to Malfunction
Time Frame
Approximately 18 months
Title
Overall Cause
Description
Catheter Loss Due to All Causes
Time Frame
Approximately 18 months
Secondary Outcome Measure Information:
Title
Death
Description
Number of deaths reported during the study period
Time Frame
Approximately 18 months
Title
Arrhythmia
Description
Incidence of significant arrhythmia during dialysis requiring urgent intervention
Time Frame
Approximately 18 months
Title
Hemodynamic Instability
Description
Incidence of extreme hypotension or hypertension requiring urgent intervention
Time Frame
Approximately 18 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients presenting over the age of 18 requiring hemodialysis via CVCs were eligible.
Exclusion Criteria:
Having a poor venous system with inadequate blood flow for appropriate HD.
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
30668833
Citation
El-Hennawy AS, Frolova E, Romney WA. Sodium bicarbonate catheter lock solution reduces hemodialysis catheter loss due to catheter-related thrombosis and blood stream infection: an open-label clinical trial. Nephrol Dial Transplant. 2019 Oct 1;34(10):1739-1745. doi: 10.1093/ndt/gfy388.
Results Reference
derived
Learn more about this trial
Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation
We'll reach out to this number within 24 hrs